Completed PHASE3 INTERVENTIONAL NCT00242346

High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to Severe Proteinuria

Sponsor: AstraZeneca

Conditions Proteinuria

Interventions candesartan cilexetil

Updated 6 times since 2017 Last updated: Dec 17, 2007 Started: Apr 30, 2003 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Proteinuria and is currently completed. AstraZeneca leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Calgary, Canada , Courtice, Canada , Edmonton, Canada , Greater Sudbury, Canada , Greenfield Park, Canada , Halifax, Canada , Kelowna, Canada , Kitchener, Canada , Laval, Canada , London, Canada and 16 more locations